Novartis, Ionis’ experimental heart drug misses key goal in trial
Novartis and Ionis Pharmaceuticals reported that their experimental heart drug, pelacarsen, failed to reduce the risk of major heart attacks and strokes in a late-stage trial. The drug, targeting genetically inherited cholesterol Lp(a), lowered Lp(a) levels but did not meet its primary endpoint. Novartis shares fell 5%, and Ionis shares dropped 12% in aftermarket trading. The companies plan to present full trial data at an upcoming medical congress.
How this was made
The 30-second read
Why it matters
The trial failure undermines expectations for a $10B revenue opportunity from pelacarsen, increasing uncertainty for the company's pipeline.
Market read
First report of a pivotal cardiovascular trial miss, prompting immediate price declines for both Novartis and Ionis.
What to watch
Potential positive data from remibrutinib and del‑desiran could offset the setback.
Background
Novartis is navigating major patent expiries and seeks growth from its cardiovascular pipeline.
Ticker impact
Novartis' late‑stage trial of pelacarsen failed to reduce heart attacks and strokes, causing a 5% share drop.
Downward pressure on NVS over the next few days.
First disclosure of a pivotal trial failure for a major pipeline asset; market reacted immediately with a 5% decline.
Ionis Pharmaceuticals, partner on pelacarsen, fell 12% in aftermarket trading after the trial miss.
Further downside for IONS in the short term.
Direct exposure to the failed trial; significant price move on news release.
Market effects
Cardiovascular drug pipeline valuations may be reassessed, affecting peers developing Lp(a) therapies.
European biotech indices could see modest pressure.
Highlights risk in late‑stage cardiovascular trials worldwide.
Counterpoint
If deeper Lp(a) lowering can be demonstrated later, the market may overreact to this single miss.
Key entities
- companyNovartis
Swiss pharmaceutical giant (ticker NVS).
- companyIonis Pharmaceuticals
Partner developing pelacarsen (ticker IONS).
